Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Waldenstrom Macroglobulinemia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

venetoclax 26ibrutinib 23Rituximab 22Cyclophosphamide 21obinutuzumab 18acalabrutinib 18fludarabine phosphate 13fludarabine 13zanubrutinib 8Bendamustine Hydrochloride 8pirtobrutinib 7Biopsy 7Specimen Handling 6Lenalidomide 6CT-P10 6Whole-Body Irradiation 5Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4duvelisib 3Melphalan 3Chlorambucil 3Busulfan 3idelalisib 2daratumumab 2Vincristine 2Prednisone 2Patient Reported Outcome Measures 2Observation 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Pharmacogenomic Testing × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡